Source: Fox News
Summary
A federal appeals court has blocked the mailing of the abortion pill mifepristone under current FDA rules, a move that could restrict abortion pill access across the country. The ruling restores a requirement that women see a medical professional to obtain a mifepristone prescription, which had been lifted during the COVID-19 pandemic. The decision has been praised by pro-life groups and criticized by pro-choice advocates, and is expected to be appealed to the Supreme Court.
Our Reading
Once again, the discussion returns to a familiar question.
The appeals court ruling blocks mail-order distribution of mifepristone, requiring it to be dispensed in person under earlier safety protocols. Judges criticized the FDA’s handling of the drug’s safety data, saying the agency had “previously eliminated the requirement to report mifepristone’s adverse events.” The ruling also sided with arguments from pro-life states, including Louisiana, which said federal policy undermined their abortion laws. Pro-life groups praised the decision, while pro-choice advocates sharply criticized it.
The ruling sets up a likely appeal to the Supreme Court, where a new challenge to federal authority over abortion drug regulation could take center stage.
Author: Evan Null
